Edgewise Therapeutics
Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors
Edgewise Therapeutics; Christopher Martin; Board of Directors; biotech executive; commercial leadership; Becker muscular dystrophy; cardiovascular asset; Verona Pharma; Merck acquisition
Edgewise Therapeutics Sees 50% Stock Surge Following Positive Safety Data for Heart Disease Drug EDG-7500
Edgewise Therapeutics, EDG-7500, Heart Disease, Cardiomyopathy, Stock Surge, Safety Data, Camzyos Rival